Energy depletion in seizures: anaplerosis as a strategy for future therapies

Stjepana Kovac1, Andrey Y Abramov, Matthew C Walker

  • 1UCL Institute of Neurology, University College London, Queen Square, WC1N 3BG London, UK. s.kovac@ion.ucl.ac.uk

Neuropharmacology
|June 5, 2012
PubMed

Insights

Energy deficits contribute to seizures. Replenishing tricarboxylic acid (TCA) cycle substrates, like pyruvate, may suppress seizure activity and prevent neuronal injury, offering new therapeutic targets for epilepsy.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Epilepsy Research

Background:

  • Seizure activity causes energy failure and neuronal damage, leading to cognitive deficits.
  • Genetic mutations impacting cellular energy homeostasis are linked to epilepsy.
  • The ketogenic diet's efficacy in epilepsy may stem from enhanced energetic substrates.

Purpose of the Study:

  • To review the role of tricarboxylic acid (TCA) cycle deficits in seizure generation.
  • To highlight TCA substrate supplementation as a potential therapeutic strategy for seizures.
  • To explore pyruvate's neuroprotective effects against seizure-induced cell death.

Main Methods:

  • Literature review focusing on TCA cycle function in epilepsy.
  • Analysis of evidence linking energy metabolism to epileptogenesis.
  • Examination of studies on anaplerotic substrate supplementation.

Main Results:

  • Evidence suggests TCA cycle deficits contribute to seizure generation.
  • Pyruvate demonstrates seizure-suppressive effects and protects against seizure-induced neuronal death.
  • Supplementation of TCA cycle substrates shows promise in mitigating seizure-related pathology.

Conclusions:

  • Energy failure is a key factor in seizure development and progression.
  • TCA cycle anaplerosis, particularly with pyruvate, represents a promising therapeutic avenue.
  • Targeting energy depletion in seizures warrants further translational research for epilepsy treatment.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...